Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Share-based Compensation (2016 - 2025)

Dare Bioscience (DARE) has disclosed Share-based Compensation for 11 consecutive years, with $403027.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 23.02% year-over-year to $403027.0, compared with a TTM value of $1.6 million through Sep 2025, down 30.21%, and an annual FY2024 reading of $2.2 million, down 12.94% over the prior year.
  • Share-based Compensation was $403027.0 for Q3 2025 at Dare Bioscience, up from $359018.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $650186.0 in Q2 2023 and bottomed at $359018.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $506923.4, with a median of $532133.0 recorded in 2022.
  • The sharpest move saw Share-based Compensation skyrocketed 127.5% in 2021, then plummeted 39.88% in 2025.
  • Year by year, Share-based Compensation stood at $388806.0 in 2021, then surged by 36.86% to $532133.0 in 2022, then grew by 16.47% to $619791.0 in 2023, then dropped by 21.06% to $489260.0 in 2024, then fell by 17.63% to $403027.0 in 2025.
  • Business Quant data shows Share-based Compensation for DARE at $403027.0 in Q3 2025, $359018.0 in Q2 2025, and $377357.0 in Q1 2025.